In recent evidence-based interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with JIA, adalimumab is recommended as the preferred TNF-α inhibitor [23]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.